Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | TP53 | P04637 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.42 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7837255 | 0.84 | MTNR1A (0.58) | MAPTMTNR1AMTNR1B | |
| SCHEMBL3954003 | 0.80 | L3MBTL1 (0.49) | LMNAPTGS2L3MBTL1MTNR1AMTNR1B | |
| SCHEMBL5623096 | 0.80 | MAPT (0.49) | MAPTTP53LMNAL3MBTL1GAA | |
| SCHEMBL4707041 | 0.80 | LMNA (0.37) | MAPTTP53LMNAL3MBTL1RXFP1 | |
| SCHEMBL5622754 | 0.78 | MTNR1A (0.61) | MAPTPTGS2L3MBTL1NPSR1MTNR1A | |
| SCHEMBL5621752 | 0.78 | NOD2 (0.53) | MAPTLMNANPSR1TSHRRXFP1 | |
| SCHEMBL29262518 | 0.78 | F10 (0.44) | MAPTTP53LMNAL3MBTL1TSHR | |
| SCHEMBL5917423 | 0.78 | PTGS2 (0.46) | MAPTTP53LMNAPTGS2L3MBTL1 | |
| SCHEMBL19252931 | 0.78 | PTGS2 (0.45) | MAPTPTGS2L3MBTL1GAANPSR1 | |
| SCHEMBL28156085 | 0.77 | MAPT (0.45) | MAPTTP53LMNAPTGS2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-8343981-B2 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | AICURIS GMBH & CO. KG (DE) | 2013-01-01 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | BAYER HEALTHCARE AG (DE) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185121-A1 | Heterocyclyl-substituted dihydroquinazolines and their use as antiviral agents | TYMP, RPL35, EIF2AK2 | MAPT 2799/4885TP53 404/4885LMNA 1763/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.